Skip to main content

Table 1 Eligibility and exclusion criteria of this study

From: Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial

Eligibility criteria

Study I

1. Patients who were 18 to 80 years of age.

2. Patients meet the criteria for sepsis which defined by the surviving sepsis campaign.

2.1 Patients had a documented or suspected infection

2.2 Patients had some of the following conditions:

2.2.1 Fever (>38.3 °C) or Hypothermia (<36 °C)

2.2.2 Heart rate >90 beats/min;

2.2.3 White blood cell count >12 × 109/L or <4 × 109/L

2.2.4 Tachypnea

2.2.5 Altered mental status

2.2.6 Significant edema or positive fluid balance (>20 mL/kg/24 h)

2.2.7 Plasma procalcitonin more than two SD above the normal value

2.2.8 Arterial hypoxemia (PaO2/FiO2 <300)

2.2.9 Creatinine increase >44.2 μmol/L

2.2.10 Arterial hypotension (SBP <90 mmHg, MAP <70 mmHg)

2.2.11 Coagulation abnormalities (INR >1.5 or APTT >60 s)

2.2.12 Thrombocytopenia (platelet count <100 × 109/L)

2.2.13 Hyperbilirubinemia (plasma total bilirubin >70 mmol/L)

2.2.14 Hyperlactatemia (>1 mmol/L)

2.2.15 Decreased capillary refill or mottling

3. Patients whose platelet counts were under 100 × 109/L.

Study II

1. Patients whose platelet counts were under 50 × 109/L.

2. Patients meet the criteria for severe sepsis which defined by the surviving sepsis campaign.

2.1 Patients had sepsis-induced tissue hypoperfusion or organ dysfunctionn (any of the following thought to be due to the infection)

2.1.1 Sepsis-induced hypotension

2.1.2 Hyperlactatemia (>2 mmol/L)

2.1.3 Urine output <0.5 mL/kg/h for more than 2 h despite adequate fluid resuscitation

2.1.4 Acute lung injury with PaO2/FiO2 <250

2.1.5 Creatinine >2.0 mg/dL (176.8 mol/L)

2.1.6 Bilirubin >2 mg/dL (34.2 mol/L)

2.1.7 Coagulation abnormalities (INR >1.5)

2.1.8 Thrombocytopenia (platelet count <100 × 109/L)

Exclusion criteria

 1. Patients with malignancies or bone marrow stem cell disorders within the last 2 years

 2. Patients who received chemotherapy or immunosuppressive agents within 6 months

 3. Patients who had a history of ITP or such autoimmune diseases

 4. Patients after cardiopulmonary resuscitation (CPR)

 5. Patients who are less than 18 years or more than 85 years of age

 6. Pregnant or puerperal patients

 7. Patients having acute gastrointestinal hemorrhage

 9. Patients who have a history of bone marrow, lung, liver, kidney, or small bowel transplantation

 10. Patients with end-stage hepatic or renal failure

 11. Patients with disseminated intravascular coagulation (DIC)

 12. Patients with drug (antibiotics or heparin)-associated thrombocytopenia

 13. Gut failure or strict nil by mouth following surgery